Maneka Mirchandaney
Stock Analyst at Evercore ISI Group
(0.27)
# 4,119
Out of 4,854 analysts
7
Total ratings
28.57%
Success rate
-28.86%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Maneka Mirchandaney
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRNX Crinetics Pharmaceuticals | Maintains: Outperform | $41 → $48 | $33.00 | +45.45% | 2 | Sep 11, 2023 | |
| INKT MiNK Therapeutics | Maintains: Outperform | $40 → $30 | $7.39 | +305.95% | 2 | Mar 22, 2023 | |
| INCY Incyte | Downgrades: In-Line | $90 → $78 | $68.76 | +13.44% | 1 | Aug 3, 2022 | |
| VRDN Viridian Therapeutics | Initiates: Outperform | $40 | $14.68 | +172.48% | 1 | Oct 12, 2021 | |
| HOWL Werewolf Therapeutics | Initiates: Outperform | $23 | $1.42 | +1,519.72% | 1 | May 25, 2021 |
Crinetics Pharmaceuticals
Sep 11, 2023
Maintains: Outperform
Price Target: $41 → $48
Current: $33.00
Upside: +45.45%
MiNK Therapeutics
Mar 22, 2023
Maintains: Outperform
Price Target: $40 → $30
Current: $7.39
Upside: +305.95%
Incyte
Aug 3, 2022
Downgrades: In-Line
Price Target: $90 → $78
Current: $68.76
Upside: +13.44%
Viridian Therapeutics
Oct 12, 2021
Initiates: Outperform
Price Target: $40
Current: $14.68
Upside: +172.48%
Werewolf Therapeutics
May 25, 2021
Initiates: Outperform
Price Target: $23
Current: $1.42
Upside: +1,519.72%